A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy

Overview

Journal Adv Urol

Publisher Wiley

Specialty Urology

Date 2011 Nov 24

PMID 22110495

Citations 6

Authors

Atsunari Kawashima

Hitoshi Takayama

Akira Tsujimura

Affiliations

Soon will be listed here.

Abstract

The excision repair cross-complementing group 1 (ERCC1) gene performs a critical incision step in DNA repair and is reported to be correlated with carcinogenesis and resistance to drug or ionizing radiation therapy. We reviewed the correlation between ERCC1 and bladder cancer. In carcinogenesis, several reports discussed the relation between ERCC1 single nucleotide polymorphisms and carcinogenesis in bladder cancer only in case-control studies. Regarding the relation between ERCC1 and resistance to chemoradiotherapy, in vitro and clinical studies indicate that ERCC1 might be related to resistance to radiation therapy rather than cisplatin therapy. It is controversial whether ERCC1 predicts prognosis of bladder cancer treated with cisplatin-based chemotherapy. Tyrosine kinase receptors or endothelial-mesenchymal transition are reported to regulate the expression of ERCC1, and further study is needed to clarify the mechanism of ERCC1 expression and resistance to chemoradiotherapy in vitro and to discover novel therapies for advanced and metastatic bladder cancer.

Citing Articles

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.

Rajendran G, Taylor 3rd J, Woolbright B Cancer Drug Resist. 2022; 4(1):69-84.

PMID: 35582013 PMC: 9019192. DOI: 10.20517/cdr.2020.69.

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.

Song W, Ma H Onco Targets Ther. 2016; 9:3465-71.

PMID: 27366083 PMC: 4913982. DOI: 10.2147/OTT.S101319.

Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins.

Jeong Y, Kim M, Lee J, Kim E, Ha H PLoS One. 2015; 10(11):e0143596.

PMID: 26599019 PMC: 4657889. DOI: 10.1371/journal.pone.0143596.

Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.

Chen L, Liu T, Zhou J, Wang Y, Wang X, Di W PLoS One. 2014; 9(12):e115708.

PMID: 25545012 PMC: 4278743. DOI: 10.1371/journal.pone.0115708.

Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.

Shilkrut M, Wu A, Thomas D, Hamstra D Mol Clin Oncol. 2014; 2(3):479-487.

PMID: 24772321 PMC: 3999124. DOI: 10.3892/mco.2014.264.

References

Park C, Bessho T, Matsunaga T, Sancar A . Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem. 1995; 270(39):22657-60. DOI: 10.1074/jbc.270.39.22657. View

Marechal R, Mackey J, Lai R, Demetter P, Peeters M, Polus M . Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009; 15(8):2913-9. DOI: 10.1158/1078-0432.CCR-08-2080. View

Soria J . ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol. 2007; 25(19):2648-9. DOI: 10.1200/JCO.2007.11.3167. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Sayan A, Griffiths T, Pal R, Browne G, Ruddick A, Yagci T . SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A. 2009; 106(35):14884-9. PMC: 2736415. DOI: 10.1073/pnas.0902042106. View

Kogevinas M, t Mannetje A, Cordier S, Ranft U, Gonzalez C, Vineis P . Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2004; 14(10):907-14. DOI: 10.1023/b:caco.0000007962.19066.9c. View

Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K . Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol. 2004; 34(3):124-30. DOI: 10.1093/jjco/hyh026. View

Chakravarti A, Winter K, Wu C, Kaufman D, Hammond E, Parliament M . Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based.... Int J Radiat Oncol Biol Phys. 2005; 62(2):309-17. DOI: 10.1016/j.ijrobp.2004.09.047. View

Stern M, Lin J, Figueroa J, Kelsey K, Kiltie A, Yuan J . Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 2009; 69(17):6857-64. PMC: 2782435. DOI: 10.1158/0008-5472.CAN-09-1091. View

10.

Kuraoka I, Kobertz W, Ariza R, Biggerstaff M, Essigmann J, Wood R . Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem. 2000; 275(34):26632-6. DOI: 10.1074/jbc.C000337200. View

11.

Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein D . NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005; 366(9486):649-59. PMC: 1459966. DOI: 10.1016/S0140-6736(05)67137-1. View

12.

Matullo G, Dunning A, Guarrera S, Baynes C, Polidoro S, Garte S . DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2005; 27(5):997-1007. DOI: 10.1093/carcin/bgi280. View

13.

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

14.

Gregg S, Robinson A, Niedernhofer L . Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease. DNA Repair (Amst). 2011; 10(7):781-91. PMC: 3139823. DOI: 10.1016/j.dnarep.2011.04.026. View

15.

Warnecke-Eberz U, Metzger R, Miyazono F, Baldus S, Neiss S, Brabender J . High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004; 10(11):3794-9. DOI: 10.1158/1078-0432.CCR-03-0079. View

16.

Hsu D, Lan H, Huang C, Tai S, Chang S, Tsai T . Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16(18):4561-71. DOI: 10.1158/1078-0432.CCR-10-0593. View

17.

Choudhury A, Nelson L, Teo M, Chilka S, Bhattarai S, Johnston C . MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010; 70(18):7017-26. PMC: 2941719. DOI: 10.1158/0008-5472.CAN-10-1202. View

18.

Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S . Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev. 2005; 14(11 Pt 1):2569-78. DOI: 10.1158/1055-9965.EPI-05-0189. View

19.

Hagan M, Winter K, Kaufman D, Wajsman Z, Zietman A, Heney N . RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003; 57(3):665-72. DOI: 10.1016/s0360-3016(03)00718-1. View

20.

Shipley W, Prout Jr G, Einstein A, Coombs L, Wajsman Z, Soloway M . Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987; 258(7):931-5. View